- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT06089616
Eine Studie zur Dokumentation und weiteren Beschreibung der langfristigen Sicherheit und Wirksamkeit von Palovaroten bei Teilnehmern mit Fibrodysplasia Ossificans Progressiva (FOP) (FOPal)
Eine internationale Beobachtungsregisterstudie zur weiteren Beschreibung der langfristigen Sicherheit und Wirksamkeit von Palovaroten bei Patienten mit Fibrodysplasia Ossificans Progressiva (FOP)
The participants in this registry study will have fibrodysplasia ossificans progressiva (FOP).
FOP is an ultra-rare, severely disabling disease characterized by new bone formation in areas of the body where bone is not normally present (heterotopic ossification (HO)).
HO is often preceded by painful, recurrent episodes of soft tissue swelling (flare-ups).
This registry study will take place in countries where the treatment, known as palovarotene, has been approved for use. Participants will either be treated with palovarotene (i.e already be receiving palovarotene as prescribed by their treating physician according to locally approved product information) or untreated with palovarotene.
The main aim of this registry study will be to collect and assess real-world safety data on children and adult participants with FOP treated with palovarotene.
This registry study will also describe the effectiveness of palovarotene in exposed participants, including the effect on everyday activities and physical performance.
In addition, this registry study aims to descriptively compare key safety outcomes (i.e. flare-up episodes, growth outcomes, and bone fractures) between participants exposed and unexposed to palovarotene.
Studienübersicht
Status
Bedingungen
Studientyp
Einschreibung (Geschätzt)
Kontakte und Standorte
Studienkontakt
- Name: Ipsen Clinical Study Enquiries
- Telefonnummer: see email
- E-Mail: clinical.trials@ipsen.com
Studienorte
-
-
-
Edmonton, Kanada
- Rekrutierung
- Edmonton Clinic Health Academy (ECHA)- University of Alberta
-
Oakville, Kanada
- Aktiv, nicht rekrutierend
- Bone Research and Education Centre
-
Toronto, Kanada
- Rekrutierung
- University Health Network (UHN) - Toronto General
-
-
-
-
California
-
San Francisco, California, Vereinigte Staaten, 94103
- Rekrutierung
- The Regents of the University of California
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19104
- Rekrutierung
- The Trustees of the University of Pennsylvania, Office of Clinical Research-Legal Services, Perelman School of Medicine
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Adults and children with FOP who have been prescribed palovarotene, as per local label, by their treating physician for which informed consent has been obtained and maintained. Participants cannot be included if they are currently participating in a palovarotene clinical trial or an interventional clinical trial for FOP or if they have any contraindication for palovarotene (except for pregnant women who have previously received and discontinued palovarotene at any time during the pregnancy and who will be included for safety follow-up).
Beschreibung
Inclusion Criteria :
- Adult or child with FOP who have been prescribed palovarotene (prior to and independently of the decision to enroll the patient in this registry study and as per local label) by their treating physician according to the locally approved product information;
- Signed informed consent as per local regulations must be obtained and maintained. Consent/assent from the participant should be obtained as appropriate before any registry study data collection are conducted. If applicable, parents or legally authorized representatives must give signed informed consent.
Exclusion Criteria :
- Currently participating in a palovarotene clinical trial;
- Currently participating in any interventional clinical trial for FOP;
- Have any contraindication to palovarotene as per the locally approved label (except for pregnant women who have previously received and discontinued palovarotene at any time during the pregnancy and who will be included for safety follow-up).
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: OTHER
- Zeitperspektiven: PROSPECTIVE
Kohorten und Interventionen
Gruppe / Kohorte |
|---|
|
Exposed Cohort
Participants treated with palovarotene (i.e already be receiving palovarotene as prescribed by their treating physician according to locally approved product information) |
|
Unexposed Cohort
Participants untreated with palovarotene |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs), whether or not they are considered as related to palovarotene
Zeitfenster: From Baseline up to 30 days after the last palovarotene dose.
|
Adverse events will be coded according to MedDRA and will be classified by Preferred Term (PT) and system organ class (SOC). |
From Baseline up to 30 days after the last palovarotene dose.
|
|
Percentage of Participants With Serious and Non-serious treatment-related TEAEs
Zeitfenster: From Baseline up to 30 days after the last palovarotene dose.
|
Adverse events will be coded according to MedDRA and will be classified by PT and SOC. |
From Baseline up to 30 days after the last palovarotene dose.
|
|
Percentage of Participants With all serious TEAEs, whether or not they are considered as related to the palovarotene
Zeitfenster: From Baseline up to 30 days after the last palovarotene dose.
|
Adverse events will be coded according to MedDRA and will be classified by PT and SOC. |
From Baseline up to 30 days after the last palovarotene dose.
|
|
Percentage of Participants With nonserious TEAEs whether or not they are considered as related to the palovarotene.
Zeitfenster: From Baseline up to 30 days after the last palovarotene dose.
|
Adverse events will be coded according to MedDRA and will be classified by PT and SOC. |
From Baseline up to 30 days after the last palovarotene dose.
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Anzahl der Schübe
Zeitfenster: Von 12 Monaten vor der Aufnahme Baseline bis zu elf Jahren.
|
Von 12 Monaten vor der Aufnahme Baseline bis zu elf Jahren.
|
|
|
Anzahl der betroffenen Standorte pro Teilnehmer
Zeitfenster: Von Grundlinien und jährlich bis zu elf Jahre.
|
Von Grundlinien und jährlich bis zu elf Jahre.
|
|
|
Entwicklung des betroffenen Standorts (wie oft ein Ort betroffen ist) pro Ort
Zeitfenster: Von Grundlinien und jährlich bis zu elf Jahre.
|
Von Grundlinien und jährlich bis zu elf Jahre.
|
|
|
Durchschnittliche Dosis/Jahr Palovarotene für Teilnehmer mit FOP, die Palovaroten für chronische Behandlung ausgesetzt und nicht exponiert ist
Zeitfenster: Von Grundlinien und alle sechs Monate bis zu elf Jahre.
|
Von Grundlinien und alle sechs Monate bis zu elf Jahre.
|
|
|
Durchschnittliche Dosis/Zyklus von Palovarotene für Teilnehmer mit FOP, die Palovaroten für die Aufflackerebehandlung ausgesetzt und nicht exponiert ist
Zeitfenster: Von Grundlinien und alle sechs Monate bis zu elf Jahre.
|
Von Grundlinien und alle sechs Monate bis zu elf Jahre.
|
|
|
Change from Baseline in Cumulative Analogue Joint Involvement Scale (CAJIS) total score
Zeitfenster: From Baseline and every six months up to eleven years.
|
The CAJIS is an objective measure of joint movement completed by the Investigator to document total joint involvement. The CAJIS total score is calculated as the sum of the scores of all joints/regions and ranges from 0 (no involvement) to 30 (maximally involved). |
From Baseline and every six months up to eleven years.
|
|
Change from Baseline in use of assistive devices
Zeitfenster: From Baseline and every six months up to eleven years.
|
Assistive devices is a questionnaire to assess the assistive devices used by particpants and adaptations for their daily living. |
From Baseline and every six months up to eleven years.
|
|
Change from Baseline in percent of worst score for Fibrodysplasia Ossificans Progressiva-Physical Function Questionnaire (FOP-PFQ) total score
Zeitfenster: From Baseline and every six months up to eleven years.
|
Fibrodysplasia Ossificans Progressiva-Physical Function Questionnaire (FOP-PFQ) consists of questions which are scored on a scale of 1 to 5, lower scores indicating that the participant has more difficulties. |
From Baseline and every six months up to eleven years.
|
|
Change from Baseline in observed and percent predicted Forced Vital Capacity (FVC)
Zeitfenster: From Baseline and every six months up to eleven years.
|
The lung function parameters of observed FVC (liters) and percent predicted FVC are obtained by spirometry. |
From Baseline and every six months up to eleven years.
|
|
Change from Baseline in observed and percent predicted Forced Expiratory Volume in one second (FEV1)
Zeitfenster: From Baseline and every six months up to eleven years.
|
The lung function parameters of observed FEV1 (liters) and percent predicted FEV1 are obtained by spirometry. |
From Baseline and every six months up to eleven years.
|
|
Change from Baseline in absolute and percent predicted FEV1/FVC ratio
Zeitfenster: From Baseline and every six months up to eleven years.
|
The lung function parameters of the absolute and percent predicted FEV1/FVC ratio are obtained by spirometry. |
From Baseline and every six months up to eleven years.
|
|
Change from Baseline in observed and percent predicted Diffusion Capacity of the Lung for Carbon Monoxide (DLCO)
Zeitfenster: From Baseline and every six months up to eleven years.
|
The lung function parameters of observed (traditional unit of mL/min/mmHg or SI unit of mmol/min/kPa) and percent predicted DLCO is obtained by the DLCO test. |
From Baseline and every six months up to eleven years.
|
|
Change from Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) physical and mental function (mean global physical and mental health score converted into T-scores) for participants ≥15 years old
Zeitfenster: From Baseline and every six months up to eleven years.
|
PROMIS Global Health Scale for the adult version, the global physical health and global mental health scores will be calculated as follows:
|
From Baseline and every six months up to eleven years.
|
|
Change from Baseline in PROMIS overall quality of life (QoL) (mean total score converted into T-scores) for participants <15 years old
Zeitfenster: From Baseline and every six months up to eleven years.
|
PROMIS Global Health Scale for the paediatric version, the total score will be calculated as the sum of scores from the first 7 questions and will range from 7 (worse health) to 35 (better health). If more than 3 questions contributing to the total score are missing, the total score will not be calculated. It will be considered as missing. |
From Baseline and every six months up to eleven years.
|
|
Change from Baseline in annualized number of Investigator-reported flare-ups by body location and overall
Zeitfenster: From Baseline and every six months up to eleven years.
|
The annualized number of flare-ups will be derived from the number of flare-ups the participant experienced since last visit. |
From Baseline and every six months up to eleven years.
|
|
Number of flare-up outcomes
Zeitfenster: From Baseline and every six months up to eleven years.
|
Number of flare-up outcomes as measured by new bone growth, restricted movement at each visit will be reported. |
From Baseline and every six months up to eleven years.
|
|
Flare-up Duration
Zeitfenster: From Baseline and every six months up to eleven years.
|
Flare-up duration will be assessed by body location and overall, at each visit. |
From Baseline and every six months up to eleven years.
|
|
Movement mobility change
Zeitfenster: From Baseline and annually up to eleven years.
|
Assessed by key body location: better movement/the same movement/slightly worse movement/moderately worse movement/severely worse movement) |
From Baseline and annually up to eleven years.
|
|
Movement mobility outcomes: Percentage of participants with new bone growth overall and by flare-up status
Zeitfenster: From Baseline and every six months up to eleven years.
|
The number of extra bone growths, location of the extra bone growth, whether it was preceded by injury, illness, vaccination and/or other events, whether it was preceded by pain, soft tissue swelling, decreased range of motion, stiffness, redness, or warmth, extra bone growth start and stop date and whether it is ongoing, will be collected. |
From Baseline and every six months up to eleven years.
|
|
Percentage of participants with any fractures overall
Zeitfenster: From baseline up to 30 days after the last palovarotene dose.
|
Assessed by radiological imaging and clinical examination. |
From baseline up to 30 days after the last palovarotene dose.
|
|
Change from Baseline in annualized number of fractures by body location and overall
Zeitfenster: From baseline up to 30 days after the last palovarotene dose.
|
Assessed by radiological imaging and clinical examination. |
From baseline up to 30 days after the last palovarotene dose.
|
|
Incidence of pregnancy
Zeitfenster: From Baseline and every month up to 30 days after the last palovarotene dose.
|
A pregnant participant with FOP exposed to palovarotene will be followed throughout the pregnancy and the health status of the baby will be verified |
From Baseline and every month up to 30 days after the last palovarotene dose.
|
|
Description of pregnancy characteristics and outcomes
Zeitfenster: From the signing of the ICF and the participant will be followed throughout the pregnancy (From Baseline and every month up to 30 days after the last palovarotene dose) and the health status of the baby will be verified up until one year of age.
|
A pregnant participant with FOP exposed to palovarotene will be followed throughout the pregnancy. |
From the signing of the ICF and the participant will be followed throughout the pregnancy (From Baseline and every month up to 30 days after the last palovarotene dose) and the health status of the baby will be verified up until one year of age.
|
|
Description of pregnancy related Adverse Events (AEs)
Zeitfenster: From the signing of the ICF and the participant will be followed throughout the pregnancy (From Baseline and every month up to 30 days after the last palovarotene dose) and the health status of the baby will be verified up until one year of age.
|
A pregnant participant with FOP exposed to palovarotene will be followed throughout the pregnancy. |
From the signing of the ICF and the participant will be followed throughout the pregnancy (From Baseline and every month up to 30 days after the last palovarotene dose) and the health status of the baby will be verified up until one year of age.
|
|
Description of birth and developmental outcomes through the first year after birth
Zeitfenster: From the signing of the ICF and the participant will be followed throughout the pregnancy (From Baseline and every month up to 30 days after the last palovarotene dose) and the health status of the baby will be verified up until one year of age.
|
A pregnant participant with FOP exposed to palovarotene will be followed throughout the pregnancy. |
From the signing of the ICF and the participant will be followed throughout the pregnancy (From Baseline and every month up to 30 days after the last palovarotene dose) and the health status of the baby will be verified up until one year of age.
|
|
Description of birth and developmental outcomes through the first year after birth
Zeitfenster: From Baseline and every six months up to eleven years.
|
Linear height and knee height velocity will be derived for growing children with FOP exposed and unexposed to palovarotene until skeletal maturity or final adult height is reached. |
From Baseline and every six months up to eleven years.
|
|
Change from Baseline in height z-score
Zeitfenster: From Baseline and every six months up to eleven years.
|
Linear height z-score will be derived for growing children with FOP exposed and unexposed to palovarotene until skeletal maturity or final adult height is reached. |
From Baseline and every six months up to eleven years.
|
|
Mean difference between chronological age and bone age
Zeitfenster: From Baseline and every six months up to eleven years.
|
Bone age (assessment as per the SmPC/PI) and chronological age will be collected for growing children with FOP exposed and unexposed to palovarotene until skeletal maturity or final adult height is reached. |
From Baseline and every six months up to eleven years.
|
|
Frequency of premature physeal closure (PPC) overall
Zeitfenster: From baseline up to 30 days after the last palovarotene dose
|
Epiphyseal status ("open" or "closed") (assessment as per the SmPC/PI) will be collected for growing children with FOP exposed and unexposed to palovarotene until skeletal maturity or final adult height is reached. |
From baseline up to 30 days after the last palovarotene dose
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienleiter: Ipsen Medical, Director, Ipsen
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- CLIN-60120-453
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications.
Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.
IPD-Sharing-Zeitrahmen
Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.
IPD-Sharing-Zugriffskriterien
Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .